Price Alert

Humacyte Inc. (HUMA)

NASDAQ: HUMA · Real-Time Price · USD

2.10

0.31 (17.32%)

At close: Oct 03, 2025, 3:59 PM

2.10

0.00%

After-hours: Oct 03, 2025, 07:56 PM EDT

17.32% (1D)

Bid	2.02
Market Cap	332.78M
Revenue (ttm)	8.05M
Net Income (ttm)	-58.66M
EPS (ttm)	-0.47
PE Ratio (ttm)	-4.47
Forward PE	-5.11
Analyst	Buy
Dividends	n/a

Ask	2.1
Volume	9,152,962
Avg. Volume (20D)	4,397,600
Open	1.81
Previous Close	1.79
Day's Range	1.79 - 2.22
52-Week Range	1.15 - 6.77
Beta	1.89
Ex-Dividend Date	n/a

About HUMA

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol HUMA

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for HUMA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Humacyte Inc. is scheduled to release its earnings on Nov 7, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 weeks ago

+16.99%

Humacyte shares are trading higher after the compa... Unlock content with Pro Subscription

1 month ago

-29.44%

Humacyte shares are trading lower after the company reported worse-than-expected Q2 financial results.

News

3 days ago · zacks.com

Humacyte, Inc. (HUMA) Outperforms Broader Market: What You Need to Know

Humacyte, Inc. (HUMA) concluded the recent trading session at $1.76, signifying a +1.15% move from its prior day's close.

1 week ago · zacks.com

Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to Note

Humacyte, Inc. (HUMA) concluded the recent trading session at $1.77, signifying a -4.84% move from its prior day's close.

1 month ago · zacks.com

Is It Worth Investing in Humacyte, Inc. (HUMA) Based on Wall Street's Bullish Views?

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analy...

1 month ago · seekingalpha.com

Humacyte: Cash Burn And A Glacial Launch Overshadow VAC Progress

I maintain my Sell rating on Humacyte due to slow SYMVESS adoption, missed Q2 estimates, and ongoing operational challenges. SYMVESS's limited market, negative publicity, and CMS reimbursement hurdles...

1 month ago · seekingalpha.com

Humacyte, Inc. (HUMA) Q2 2025 Earnings Call Transcript

Humacyte, Inc. (NASDAQ:HUMA ) Q2 2025 Earnings Call August 11, 2025 8:00 AM ET Company Participants Dale A. Sander - CFO, Chief Corporate Development Officer & Treasurer Laura E.

1 month ago · zacks.com

Humacyte, Inc. (HUMA) Reports Q2 Loss, Misses Revenue Estimates

Humacyte, Inc. (HUMA) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.27 per share a year ago.